Ipca Laboratories Ltd
IPCALAB
Company Profile
Business description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Contact
No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
23,236
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 78.50 | -0.85% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 48,972.05 | 43.55 | -0.09% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,445.24 | 381.67 | -1.37% |
| NASDAQ | 23,530.76 | 326.69 | -1.37% |
| Nikkei 225 | 53,383.93 | 25.22 | 0.05% |
| NZX 50 Index | 13,423.18 | 10.31 | 0.08% |
| S&P 500 | 6,939.31 | 38.72 | -0.55% |
| S&P/ASX 200 | 8,869.10 | 54.10 | -0.61% |
| SSE Composite Index | 4,125.58 | 32.40 | -0.78% |